Cell Technology
Executive Summary
Completes $ 8.9 mil. private placement, which will be used primarily to fund expanded Phase II development of the biological response modifier Imuvert for the treatment of brain cancer. The Boulder, Colorado-based biotech firm said it "anticipates meeting with FDA in the very near future to discuss" whether Imuvert can be developed under FDA's new expedited approval procedures.